 |
| ACCUTYPE
HIV-1 Isolates & Panels |
HIV
subtype material useful for RNA assay
development, improvement and method validation.
BBI offers a collection of 40 globally
relevant HIV-1 subtypes from the Major
(M) and Outlier (O) groups featuring:
- Viral quantitation by electron microscopy
(EM)
- cGMP production of virus lots
- Verification of isolate identity
by sequence analysis
- Isolates provided by U.S. National
Institutes of Health, the U.S. Department
of Defense and the European Network
for Virological Evaluation of New anti-HIV
Therapies as part of a Material Transfer
Agreement with BBI Diagnostics
|
|
| Anti-HIV
Candidate Evaluation Panel |
Panel
members are viable, cultured virus isolates from
all subtypes.
Anti-HIV Candidate Evaluation Panel members are
viable, cultured virus isolates selected to support
in-vitro drug susceptibility studies that use
infected cells to assess anti-HIV activity of
candidate compounds.
|
COMPARE
CANDIDATES WITH
20 ISOLATES FROM ALL HIV SUBTYPES |
| |
IC50 |
Panel
Member ID |
HIV-1
Subtype |
Your
Candidate Drug |
Zidovudine
nM* |
Indinavir
nM* |
| PRD320-01 |
A |
35.2 |
446.4 |
40.3 |
| PRD320-02 |
A |
17.6 |
3.2 |
29.5 |
| PRD320-03 |
CRF02_AG |
5.4 |
7.1 |
6.1 |
| PRD320-04 |
CRF02_AG |
15.7 |
336.8 |
12.2 |
| PRD320-05 |
B |
11.7 |
2369.1 |
8.3 |
| PRD320-06 |
B |
4 |
33 |
984.9 |
| PRD320-07 |
C |
23.5 |
428.1 |
25.4 |
| PRD320-08 |
C |
26.3 |
30.6 |
24.8 |
| PRD320-09 |
D |
7.7 |
1.5 |
78.5 |
| PRD320-10 |
D |
14.1 |
18.7 |
28.3 |
| PRD320-11 |
CRF01_AE |
62.6 |
446.4 |
40.3 |
| PRD320-12 |
CRF01_AE |
34.8 |
3.2 |
29.5 |
| PRD320-13 |
F |
5.9 |
7.1 |
6.1 |
| PRD320-14 |
F |
16.2 |
336.8 |
12.2 |
| PRD320-15 |
G |
10 |
2369.1 |
8.3 |
| PRD320-16 |
G |
66 |
33 |
984.9 |
| PRD320-17 |
H |
22.8 |
30.6 |
24.8 |
| PRD320-18 |
O |
37.9 |
428.1 |
25.4 |
| PRD320-19 |
O |
4.4 |
1.5 |
78.5 |
| PRD320-20 |
HIV-2 |
55.1 |
18.7 |
28.3 |
| *
IC50 results are examples, not actual
values |
|
